Progyny, Inc. $PGNY Shares Sold by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. reduced its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 40.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 259,285 shares of the company’s stock after selling 175,735 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Progyny were worth $6,658,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd bought a new stake in Progyny in the fourth quarter valued at $25,000. Hantz Financial Services Inc. grew its position in shares of Progyny by 79.4% during the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after acquiring an additional 742 shares during the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Progyny in the 2nd quarter worth about $77,000. Quarry LP lifted its position in Progyny by 2,004.1% in the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after purchasing an additional 3,427 shares during the last quarter. Finally, New Age Alpha Advisors LLC bought a new stake in Progyny in the 4th quarter valued at about $94,000. 94.93% of the stock is currently owned by institutional investors.

Progyny Price Performance

PGNY stock opened at $28.51 on Friday. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $28.75. The firm has a market cap of $2.23 billion, a PE ratio of 37.03, a P/E/G ratio of 2.42 and a beta of 1.03. The firm has a 50 day simple moving average of $23.45 and a 200 day simple moving average of $22.39.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.24. The firm had revenue of $328.50 million during the quarter, compared to analysts’ expectations of $326.46 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm’s revenue for the quarter was down 26.4% compared to the same quarter last year. During the same period last year, the firm posted $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, sell-side analysts expect that Progyny, Inc. will post 1.07 earnings per share for the current year.

Progyny announced that its board has initiated a stock buyback program on Tuesday, May 26th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to buy up to 10.3% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s management believes its shares are undervalued.

Wall Street Analyst Weigh In

Several research firms recently commented on PGNY. BTIG Research lowered their target price on Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Thursday, March 5th. KeyCorp lowered their price target on Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Jefferies Financial Group restated a “buy” rating and set a $30.00 price objective on shares of Progyny in a research note on Friday, March 6th. Barclays upped their price objective on shares of Progyny from $23.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Finally, Truist Financial increased their target price on shares of Progyny from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Eleven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.92.

Insider Buying and Selling at Progyny

In other news, EVP Allison Swartz sold 1,199 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $25.02, for a total transaction of $29,998.98. Following the completion of the sale, the executive vice president directly owned 83,316 shares of the company’s stock, valued at $2,084,566.32. This trade represents a 1.42% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of Progyny stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total value of $39,137.40. Following the completion of the transaction, the insider owned 59,117 shares in the company, valued at $1,512,212.86. The trade was a 2.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 36,916 shares of company stock worth $939,875. 9.90% of the stock is owned by insiders.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.